Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Part 2 is now closed to accrual.
Prostate Cancer
DRUG: AMG 509|DRUG: Abiraterone|DRUG: Enzalutamide
Incidence of treatment-emergent adverse events, 3 years|Incidence of treatment-related adverse events, 3 years|Dose limiting toxicities (DLTs), 3 years|Number of participants with changes in vital signs, 3 years|Number of participants with changes in the electrocardiogram (ECG) records, 3 years|Number of participants with changes in the clinical laboratory tests results, 3 years
Maximum serum concentration (Cmax) for AMG 509, To characterize the pharmacokinetics (PK) of AMG 509, 3 years|Time to maximum serum concentration (Tmax) for AMG 509, To characterize the pharmacokinetics (PK) of AMG 509, 3 years|Minimum serum concentration (Cmin) for AMG 509, To characterize the pharmacokinetics (PK) of AMG 509, 3 years|Area under the concentration-time curve (AUC) over the dosing interval for AMG 509, To characterize the pharmacokinetics (PK) of AMG 509, 3 years|Accumulation following multiple dosing for AMG 509, To characterize the pharmacokinetics (PK) of AMG 509, 3 years|Objective response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with Prostate Cancer Working Group 3 (PCWG3) modifications, To evaluate preliminary anti-tumor activity of AMG 509, 3 years|Prostate specific antigen (PSA) response, To evaluate preliminary anti-tumor activity of AMG 509, 3 years|PSA decline of at least 50% from baseline at 12 weeks, To evaluate preliminary anti-tumor activity of AMG 509, Week 12|Duration of response (DOR) (radiographic and PSA), To evaluate preliminary anti-tumor activity of AMG 509, 3 years|Time to progression (radiographic and PSA), To evaluate preliminary anti-tumor activity of AMG 509, 3 years|Progression-free survival (PFS) (radiographic and PSA), To evaluate preliminary anti-tumor activity of AMG 509, 3 years|6 month radiographic PFS, To evaluate preliminary anti-tumor activity of AMG 509, 6 months|1, 2, and 3-year radiographic PFS, To evaluate preliminary anti-tumor activity of AMG 509, Year 1, 2, and 3|1, 2, and 3-year overall survival (OS), To evaluate preliminary anti-tumor activity of AMG 509, Year 1, 2, and 3|Circulating tumor cells response (CTC0), To evaluate preliminary anti-tumor activity of AMG 509, 3 years|Rate of circulating tumor cells (CTC) conversion, To evaluate preliminary anti-tumor activity of AMG 509, 3 years|Time to symptomatic skeletal events, To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints., 3 years|Alkaline phosphatase (total, bone), To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints., 3 years|Lactate dehydrogenase (LDH), To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints., 3 years|Hemoglobin, To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints., 3 years|Urine N-telopeptide, To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints., 3 years|Neutrophil-to-lymphocyte ratio, To evaluate preliminary anti-tumor activity of AMG 509. Measure of disease burden based on PCWG3-recommended endpoints., 3 years
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Part 2 is now closed to accrual.